About the Company
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IONS News
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.
Ionis Pharmaceuticals Inc IONS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Ionis Pharmaceuticals Faces Sell Rating Amid Weak Clinical Results and Rising Competition
Ionis Pharmaceuticals (IONS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst William Pickering from Bernstein reiterated a Sell rating on ...
Ionis Pharmaceuticals gets grant for modified oligonucleotide for reducing lRRK2 rna in neurodegenerative diseases
Discover how Ionis Pharmaceuticals' patent for modified oligonucleotides offers hope in treating Parkinson's disease by reducing LRRK2 levels and alleviating symptoms. Explore the groundbreaking ...
Ionis to hold first quarter 2024 financial results webcast
CARLSBAD, Calif., April 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to ...
Buy Rating on Ionis Pharmaceuticals: Promising Clinical Data and Strategic Market Positioning for Olezarsen
David Lebovitz, an analyst from Citi, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The associated price target is $60.00. David Lebovitz has given his Buy rating ...
Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
April 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine ...
Ionis to hold first quarter 2024 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
CARLSBAD, Calif., April 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational ...
Loading the latest forecasts...